시장보고서
상품코드
939923

세계의 게노믹스 파트너링 조건과 합의(2014-2020년)

Global Genomics Partnering Terms and Agreements 2015 to 2022

발행일: | 리서치사: Current Partnering, a division of Wildwood Ventures Limited | 페이지 정보: 영문 500+ Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 게노믹스 관련 시장에서 제휴 계약의 동향과 조건에 대해 조사분석했으며, 최근 동향, 대표적인 거래의 개요, 활발한 사업자, 제휴 계약 디렉토리, 주요 거래(금액별) 등에 관한 정보를 정리하여 전해드립니다.

목차

개요

제1장 서론

제2장 게노믹스 관련 계약 동향

  • 서론
  • 과거 수년간의 제휴
  • 가장 활발한 사업자
  • 게노믹스 파트너링 : 거래 유형별
  • 게노믹스 파트너링 : 치료 분야별
  • 게노믹스 파트너링 : 업계 부문별
  • 게노믹스 관련 거래조건
    • 거래 총액
    • 선금 지불액
    • 목표 달성 보장금
    • 로열티료율
  • 게노믹스 거래의 구조
  • a. 사례 연구 1 : RRD International & Dipexium Pharmaceuticals
  • b. 사례 연구 2 : Hospira & Cempra Pharmaceutical
  • c. 사례 연구 3 : Astellas & Optimer Pharmaceuticals

제3장 주요 게노믹스 관련 거래

  • 서론
  • 주요 거래 : 금액별

제4장 가장 활발한 게노믹스 관련 사업자

  • 서론
  • 가장 활발한 사업자
  • 가장 활발한 사업자의 개요

제5장 게노믹스 관련 계약 디렉토리

  • 서론
  • 게노믹스 관련 계약 디렉토리

제6장 게노믹스 관련 계약 : 기술 유형별

제7장 제휴 리소스 센터

  • 온라인 제휴
  • 제휴 이벤트
  • 참고 문헌

부록

KSA 20.06.17

The Global Genomics Partnering Terms and Agreements 2015 to 2022 report provides comprehensive understanding and unprecedented access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies

The Global Genomics Partnering Terms and Agreements 2015 to 2022 report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in genomics partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Genomics partnering contract documents

Top genomics deals by value

The Global Genomics Partnering Terms and Agreements report provides an understanding and access to the genomics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter genomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors genomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains links to online copies of actual genomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
  • The initial chapters of this report provide an orientation of genomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in genomics dealmaking since 2015, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading genomics deals since 2015. Deals are listed by headline value, signed by big pharma, most active genomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in genomics dealmaking with a brief summary followed by a comprehensive listing of genomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2015, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 provides a comprehensive and detailed review of genomics partnering deals signed and announced since Jan 2015. The chapter is organized by specific genomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by genomics partnering company A-Z, deal type definitions and genomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in genomics partnering and dealmaking since 2015.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genomics technologies and products.

Report scope

  • Global Genomics Partnering Terms and Agreements 2015 to 2022 is intended to provide the reader with an in-depth understanding and access to genomics trends and structure of deals entered into by leading companies worldwide.

Global Genomics Partnering Terms and Agreements 2015 to 2022 includes:

  • Trends in genomics dealmaking in the biopharma industry since 2015
  • Access to headline, upfront, milestone and royalty data
  • Access to over 950 genomics deal records and contract documents where available
  • The leading genomics deals by value since 2015
  • Most active genomics dealmakers since 2015
  • The leading genomics partnering resources

In Global Genomics Partnering Terms and Agreements 2015 to 2022, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Genomics Partnering Terms and Agreements 2015 to 2022 provides the reader with the following key benefits:

  • In-depth understanding of genomics deal trends since 2015
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to genomics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of genomics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading genomics deals by value since 2015
  • Identify the most active genomics dealmakers since 2015
  • Detailed access to actual genomics contracts enter into by the leading big pharma and big biotech companies
  • Insight into the terms included in a genomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in genomics dealmaking

  • 2.1. Introduction
  • 2.2. Genomics partnering over the years
  • 2.3. Most active genomics dealmakers
  • 2.4. Genomics partnering by deal type
  • 2.5. Genomics partnering by therapy area
  • 2.6. Deal terms for genomics partnering
    • 2.6.1 Genomics partnering headline values
    • 2.6.2 Genomics deal upfront payments
    • 2.6.3 Genomics deal milestone payments
    • 2.6.4 Genomics royalty rates

Chapter 3 - Leading genomics deals

  • 3.1. Introduction
  • 3.2. Top genomics deals by value

Chapter 4 - Most active genomics dealmakers

  • 4.1. Introduction
  • 4.2. Most active genomics dealmakers
  • 4.3. Most active genomics partnering company profiles

Chapter 5 - Genomics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Genomics contracts dealmaking directory

Chapter 6 - Genomics dealmaking by technology type

Appendices

  • Appendix 1 - Genomics deals by company A-Z
  • Appendix 2 - Genomics deals by stage of development
  • Appendix 3 - Genomics deals by deal type
  • Appendix 4 - Genomics deals by therapy area
  • Appendix 5 - Deal type definitions
  • Appendix 6 - Further Reading

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Genomics partnering since 2015
  • Figure 2: Active genomics dealmaking activity sincce 2015
  • Figure 3: Genomics partnering by deal type since 2015
  • Figure 4: Genomics partnering by disease type since 2015
  • Figure 5: Genomics partnering by industry sector since 2015
  • Figure 6: Genomics deals with a headline value
  • Figure 7: Genomics deals with an upfront value
  • Figure 8: Genomics deals with a milestone value
  • Figure 9: Genomics deals with a royalty rate value
  • Figure 10: Top genomics deals by value since 2015
  • Figure 11: Most active genomics dealmakers since 2015
  • Figure 12: Genomics partnering by technology type since 2015
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제